The overall goal of this competitive renewal continues to be to understand the mechanisms involved in maintaining the survival of breast carcinoma cells in hypoxia. The work funded by this grant has pioneered studies on the central role of autocrine VEGF in the survival of breast carcinoma cells and it revealed a key role for the VEGF receptor Neuropilin-1 (NP-1) in this survival. Significant progress was made in other areas as well, but this renewal focuses specifically on the hypothesis that the progression to invasive and metastatic breast carcinoma includes the elaboration of VEGFies signaling in tumor cells.
Aim 1 will investigate the contribution of NP-1 to tumor formation and progression using conditional NP-1 knock out mice and the MMTV-MT model of mammary cancer. Also, the importance of NP-1 to the ability of human breast carcinoma cells to form xenografts and progress to metastasis will be assessed using shRNA.
Aim 2 will address the novel hypothesis that a specific plexin, plexin A1, contributes to breast carcinoma survival by functioning as a co-receptor for NP-1 to mediate VEGF16s signaling. The hypothesis that NP-1/plexin A1 signaling functions to evade apoptosis by inhibiting GSK-3|3 and activating NFicB will also be pursued in Aim 2.
Aim 3 will investigate the relationship between VEGFi65/NP-1 signaling and the dissolution of epithelial architecture that is associated with the genesis of invasive and metastatic cancers. Specifically, the hypothesis that normal mammary epithelial cells and highly differentiated carcinoma cells are independent of VEGF16s/NP-1 survival signaling but that these cells become dependent on VEGF-|65/NP-1 signaling during the epithelial to mesenchymal transition. In addition, the ability of hypoxia to stimulate an EMT by activating Akt, inhibiting GSK-Sp and inducing the expression of Snail, a transcription factor that represses E-cadherin will be studied. The contribution of VEGF to vascular and lymph angiogenesis dominated and, in fact, continues to dominate the study of this growth factor in breast and other cancers. Undoubtedly, this function of VEGF is essential. An important implication of our work, however, is that it challenges the notion that the function of VEGF in cancer is limited to angiogenesis and that therapeutic approaches based on the inhibition of VEGF function target only angiogenesis. In fact, therapy aimed at targeting either VEGF or VEGF receptors is showing considerable progress in clinical trials with late-stage cancer patients and the possibility that such therapy is targeting VEGF signaling in tumor cells is likely. For this reason, a rigorous understanding of the mechanisms used in this signaling and its relevance to breast cancer is essential.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA089209-11
Application #
7743763
Study Section
Tumor Microenvironment Study Section (TME)
Program Officer
Snyderwine, Elizabeth G
Project Start
2001-02-01
Project End
2012-12-31
Budget Start
2010-01-01
Budget End
2012-12-31
Support Year
11
Fiscal Year
2010
Total Cost
$293,995
Indirect Cost
Name
University of Massachusetts Medical School Worcester
Department
Biology
Type
Schools of Medicine
DUNS #
603847393
City
Worcester
State
MA
Country
United States
Zip Code
01655
Samanta, S; Sharma, V M; Khan, A et al. (2012) Regulation of IMP3 by EGFR signaling and repression by ERýý: implications for triple-negative breast cancer. Oncogene 31:4689-97
Jiao, Baowei; Ma, Hong; Shokhirev, Maxim N et al. (2012) Paternal RLIM/Rnf12 is a survival factor for milk-producing alveolar cells. Cell 149:630-41
Goel, Hira Lal; Chang, Cheng; Pursell, Bryan et al. (2012) VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer. Cancer Discov 2:906-21
Goel, Hira Lal; Bae, Donggoo; Pursell, Bryan et al. (2011) Neuropilin-2 promotes branching morphogenesis in the mouse mammary gland. Development 138:2969-76
Frohlich, Camilla; Nehammer, Camilla; Albrechtsen, Reidar et al. (2011) ADAM12 produced by tumor cells rather than stromal cells accelerates breast tumor progression. Mol Cancer Res 9:1449-61
Mak, Paul; Leav, Irwin; Pursell, Bryan et al. (2010) ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell 17:319-32
Bae, Donggoo; Lu, Shaolei; Taglienti, Cherie A et al. (2008) Metabolic stress induces the lysosomal degradation of neuropilin-1 but not neuropilin-2. J Biol Chem 283:28074-80
Schmidt, Melanie; Voelker, Hans-Ullrich; Kapp, Michaela et al. (2008) Expression of VEGFR-1 (Flt-1) in breast cancer is associated with VEGF expression and with node-negative tumour stage. Anticancer Res 28:1719-24
Schmidt, Melanie; Khan, Ashraf; Schmidt, Andre Michael et al. (2007) A novel breast cancer cell line initially established from pleural effusion: evolution towards a more aggressive phenotype. Int J Oncol 30:565-72
Bachelder, Robin E; Yoon, Sang-Oh; Franci, Clara et al. (2005) Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: implications for the epithelial-mesenchymal transition. J Cell Biol 168:29-33

Showing the most recent 10 out of 22 publications